Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
Benjamin Turner(Royal London Hospital), Stephen L. Hauser(University of California, San Francisco), Bruce Cree(University of California, San Francisco), Hideki Garren(Io Therapeutics (United States)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Ludwig Kappos(University Hospital of Basel), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Jian Han, Régine Buffels(Roche (Switzerland)), Damian Fiore, Caroline Papeix(Sorbonne Université)
Cited by 84
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k